Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvedBy |
2013
|
| gptkbp:component |
gptkb:linker
gptkb:monoclonal_antibody cytotoxic payload |
| gptkbp:developedBy |
multiple pharmaceutical companies
|
| gptkbp:example |
gptkb:trastuzumab_deruxtecan
gptkb:trastuzumab_emtansine disitamab vedotin |
| gptkbp:hasApprovedDrug |
gptkb:trastuzumab_emtansine
|
| gptkbp:indication |
gastric cancer
metastatic breast cancer |
| gptkbp:mechanismOfAction |
delivers cytotoxic agent to HER2-expressing cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:interstitial_lung_disease
nausea fatigue thrombocytopenia |
| gptkbp:target |
HER2
|
| gptkbp:usedFor |
HER2-positive cancer
|
| gptkbp:bfsParent |
gptkb:ARX788
|
| gptkbp:bfsLayer |
8
|
| http://www.w3.org/2000/01/rdf-schema#label |
anti-HER2 ADC
|